{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Number of patients with Flow sort diploid populations of tumor cells from FFPE tissue blocks reported as a count of participants.","groups":[{"description":"Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Treatment (Vorinostat)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"the two cases that had FFPE blocks for the study","reportingStatus":"POSTED","timeFrame":"Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months","title":"Number of Patients With Flow Sort Diploid Populations of Tumor Cells From FFPE Tissue Blocks","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}